
Medicine and Health
Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
X. Xu, T. Xie, et al.
This groundbreaking research by Xiaoyan Xu and colleagues reveals how Hsc70 can significantly enhance the efficacy of immune checkpoint therapies by promoting the degradation of PD-L1. By inhibiting the CMTM6-PD-L1 interaction, Hsc70 plays a crucial role in reducing tumor growth and improving anti-tumor immunity, particularly when paired with the Hsp90α/β inhibitor AUY-922.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.